Neurology – Page 20

Alzheimer’s Disease: Navigating Controversies and Shaping Future Strategies

By MedXY 10/10/2025

Recent advances in anti-β amyloid monoclonal antibodies offer promising reductions in Alzheimer’s disease progression but spark debate regarding their clinical impact, cost-effectiveness, and accessibility. Emerging biomarkers and preventive approaches herald a new era in personalized dementia care.

Neurology news Rheumatology

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

By MedXY 10/10/2025

In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.

Neurology news

Decoding SUDEP: Key Risk Markers and the Role of Peri-Ictal Apnoea in Epilepsy Mortality

By MedXY 10/10/2025

A decade-long prospective study identifies living alone, convulsive seizure frequency, and peri-ictal apnoea as pivotal predictors for sudden unexpected death in epilepsy (SUDEP), highlighting the potential of cardiorespiratory monitoring in risk assessment.

Neurology news Public Health

How Poor Sleep Accelerates Brain Aging: The Role of Inflammation and What You Can Do

By MedXY 10/08/2025

New research links poor sleep quality in middle-aged and older adults to accelerated brain aging, with inflammation playing a key role. Improving sleep may help slow cognitive decline and promote brain health.

Dermatology Neurology news

Transcutaneous Auricular Vagus Nerve Stimulation: A Promising New Therapy for Erythematotelangiectatic Rosacea

By MedXY 10/08/2025

A randomized trial demonstrates that 3 weeks of transcutaneous auricular vagus nerve stimulation significantly reduces facial erythema, flushing, and associated neuropsychiatric symptoms in erythematotelangiectatic rosacea, with effects persisting 24 weeks post-treatment.

Internal Medicine Neurology news

Aspirin Use in Older Adults: Insights from the ASPREE-XT Study on Healthy Lifespan

By MedXY 10/07/2025

Extended follow-up from the ASPREE-XT study shows low-dose aspirin does not improve healthy lifespan—defined as survival free of dementia, persistent disability, or death—in healthy older adults, and its risks include increased major hemorrhagic events.

Neurology news Ophthalmology

Vogt-Koyanagi-Harada Syndrome Presenting with Ophthalmic and Neurological Symptoms: A Case Report

By MedXY 10/05/2025

A 38-year-old male with bilateral blurred vision and neurological symptoms was diagnosed with Vogt-Koyanagi-Harada syndrome and managed successfully with corticosteroids and immunosuppressants.

Neurology news Public Health

Unraveling the Link Between Traumatic Brain Injury and ALS Risk: Insights From a Large UK Cohort Study

By MedXY 10/05/2025

A large retrospective cohort study reveals a transient association between traumatic brain injury (TBI) and elevated amyotrophic lateral sclerosis (ALS) risk, suggesting early ALS symptoms may predispose to injury rather than TBI causing ALS.

Neurology news

Balancing Act in Traumatic Acute Subdural Hematoma: Acute Surgery vs Conservative Management

By MedXY 10/04/2025

A multicenter study found no superior outcomes between acute surgical evacuation and conservative treatment for traumatic acute subdural hematoma, suggesting conservative management may be appropriate when surgical equipoise exists.

Neurology news Otorhinolaryngology

Unraveling the Link Between Anxiety and Dizziness in Vestibular Schwannoma Patients: Insights From a Retrospective Cohort Study

By MedXY 10/04/2025

A recent study reveals that anxiety significantly correlates with increased dizziness severity in patients with vestibular schwannoma, highlighting an underexplored psychological dimension in symptom burden and prompting calls for integrated management approaches.

Clinical Updates Neurology news Pediatrics Specialties

Memantine Shows Promise for Improving Social Impairment in Youths with Autism Spectrum Disorder

By MedXY 10/01/2025

A 12-week randomized clinical trial demonstrates memantine’s efficacy and safety in improving social impairments in youths with ASD, with elevated pgACC glutamate levels serving as a predictive biomarker for treatment response.

Neurology Pediatrics Psychiatry Specialties

Unraveling ADHD: Gut Microbial Signatures and the Role of SCFA Deficiency in Symptom Pathogenesis

By MedXY 09/29/2025

Recent research reveals distinct gut microbial and metabolic profiles linked to ADHD symptoms, highlighting short-chain fatty acid deficiency as a key mechanism driving hyperactivity and inattention.

Clinical Updates Neurology Specialties

Early-Life Gut Microbiome Maturity: A Key Regulator of Blood-Brain Barrier Integrity and Cognitive Development

By MedXY 09/29/2025

This study demonstrates that the maturity of the early-life gut microbiome influences blood-brain barrier integrity and cognitive functions, highlighting a novel therapeutic target for neurodevelopmental disorders.

Clinical Updates Neurology Specialties

NLRP3 Inflammasome and Gut Microbiota-Brain Axis: Emerging Insights into White Matter Injury After Intracerebral Hemorrhage

By MedXY 09/29/2025

This article explores how gut microbiota dysbiosis and NLRP3 inflammasome activation contribute to secondary white matter injury post-intracerebral hemorrhage, outlining mechanisms and potential therapeutic strategies.

Clinical Updates Neurology news Specialties

Microbiome Virulence Signatures in the Oral-Gut-Brain Axis: New Insights into Parkinson’s Disease and Cognitive Decline

By MedXY 09/29/2025

This study reveals how virulence factors in oral and gut microbiomes and their translocation affect cognitive impairment in Parkinson’s disease, highlighting novel biomarker potential and the importance of the oral-gut-brain axis for early diagnosis and therapeutic strategies.

Clinical Updates Neurology news Specialties

Efficacy and Acceptability of Cognitive Behavioral Therapy for Insomnia in Chronic Disease: A Comprehensive Meta-Analysis

By MedXY 09/28/2025

This meta-analysis confirms that cognitive behavioral therapy for insomnia (CBT-I) is an effective, well-accepted treatment improving sleep outcomes across diverse chronic diseases, with minimal adverse effects and potential for broad clinical application.

Neurology news Specialties

Levodopa in Acute Stroke Rehabilitation: Insights from the ESTREL Randomized Clinical Trial

By MedXY 09/28/2025

The ESTREL trial demonstrates that levodopa added to standardized rehabilitation does not significantly improve motor recovery after acute stroke, challenging its adjunctive use for enhancing neuroplasticity in stroke rehabilitation.

Clinical Updates Neurology news

Clinically Meaningful Changes in Cognitive and Functional Measures Early in Alzheimer’s Disease: Insights from Population-Based Cohorts

By MedXY 09/28/2025

This review synthesizes evidence on clinically meaningful within-patient changes in cognitive and functional assessments among individuals transitioning to mild cognitive impairment (MCI), highlighting implications for clinical trials and early intervention in Alzheimer's disease and related dementias (ADRD).

Cardiology Clinical Updates Neurology news

Electrophysiological Study Surpasses ECG in Predicting Life-Threatening Conduction Delays in Myotonic Dystrophy Type 1

By MedXY 09/27/2025

In patients with myotonic dystrophy type 1 (DM1), electrophysiological study (EPS) using the His-ventricular (HV) interval is superior to electrocardiogram (ECG) in predicting major bradyarrhythmic events, suggesting enhanced risk stratification with EPS-guided thresholds.

General Surgery Neurology news

Efficacy and Safety of Shunt Surgery in Idiopathic Normal-Pressure Hydrocephalus: Insights from a Rigorous Randomized Controlled Trial

By MedXY 09/27/2025

A double-blind, placebo-controlled trial demonstrates that shunt surgery significantly improves gait velocity and balance in patients with idiopathic normal-pressure hydrocephalus who respond to temporary CSF drainage, with mixed safety outcomes and no cognitive or urinary symptom benefits at 3 months.